Gwen A. Melincoff
Known title: DirectorCIK: 0001614890
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
COLL Outlook Supported by ADHD Trends, Low Generic Risk, Oppenheimer. Oppenheimer notes that Collegium Pharmaceutical's outlook is bolstered by strong demand for ADHD treatments and a low risk of generic competition. The firm’s focus on these areas may help sustain revenue growth. The stock is currently trading near its 52‑week low of $21.43, close to a support level that has been tested repeatedly.
Transaction History
| PLX | ▲ Buy | Grant | 7,500 | — | 9/3/2025 | View on chart |
| COLL | ▲ Buy | Grant | 7,693 | $0 | 5/16/2024 | View on chart |
| COLL | ▲ Buy | Grant | 9,792 | $0 | 5/18/2023 | View on chart |
| COLL | ▲ Buy | Grant | 14,035 | $0 | 5/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
PLX: No direct news; broader market analyst moves noted
Recent news coverage focuses on analyst actions for other companies like Netflix and SanDisk, with no specific updates reported for Protalix BioTherapeutics. The stock currently trades within its 52-week range of $1.60 to $3.19, holding above the identified support level of $2.31. While technical signals show some divergence, the lack of company-specific headlines keeps the immediate news impact low.
PLX: No direct news; broader market analyst moves noted. Recent news coverage focuses on analyst actions for other companies like Netflix and SanDisk, with no specific updates reported for Protalix BioTherapeutics. The stock currently trades within its 52-week range of $1.60 to $3.19, holding above the identified support level of $2.31. While technical signals show some divergence, the lack of company-specific headlines keeps the immediate news impact low.